Monash Biomed Profile
Key Indicators
- Authorised Capital ₹ 5.50 M
- Paid Up Capital ₹ 5.07 M
- Company Age 16 Year, 1 Day
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -50.23%
- Profit Growth -10.86%
- Ebitda -195.83%
- Net Worth -27.94%
- Total Assets -22.89%
About Monash Biomed
Monash Biomed Private Limited (MBPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 February 2009 and has a history of 16 years. Its registered office is in Delhi, India.
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.50 M and a paid-up capital of Rs 5.07 M, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Pundir and Shobhan Vyas serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U33110DL2009PTC187603
-
Company No.
187603
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Feb 2009
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Monash Biomed Private Limited offer?
Monash Biomed Private Limited offers a wide range of products and services, including Volumetric Pipette, Micropipette.
Who are the key members and board of directors at Monash Biomed?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shobhan Vyas
|
Director | 13-Feb-2009 | Current |
|
Rajendra Pundir
|
Director | 13-Feb-2009 | Current |
Financial Performance of Monash Biomed.
Monash Biomed Private Limited, for the financial year ended 2017, experienced significant reduction in revenue, with a 50.23% decrease. The company also saw a substantial fall in profitability, with a 10.86% decrease in profit. The company's net worth observed a substantial decline by a decrease of 27.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Monash Biomed?
In 2017, Monash Biomed had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Monash Biotech Private LimitedShobhan Vyas is a mutual person
-
Genesis Embryology Private LimitedShobhan Vyas is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Monash Biomed?
Unlock and access historical data on people associated with Monash Biomed, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Monash Biomed, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Monash Biomed's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
